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The peptide hormone H2 relaxin has demonstrated promise as a therapeutic, but mimetic develop-
ment has been hindered by the poorly understood relaxin receptor RXFP1 activation mechanism.
H2 relaxin is hypothesized to bind to two distinct ECD sites, which reorientates the N-terminal
LDLa module to activate the transmembrane domain. Here we provide evidence for this model in
live cells by measuring bioluminescence resonance energy transfer (BRET) between nanoluciferase-
tagged RXFP1 constructs and fluorescently labeled H2 relaxin (NanoBRET). Additionally, we validate
these results using the related RXFP2 receptor and chimeras with an inserted RXFP1-binding domain
utilizing NanoBRET and nuclear magnetic resonance studies on recombinant proteins. We therefore
provide evidence for the multi-component molecular mechanism of H2 relaxin binding to RXFP1 on
the full-length receptor in cells. Also, we show the utility of NanoBRET real-time binding kinetics to
reveal subtle binding complexities, whichmay be overlooked in traditional equilibriumbinding assays.1Florey Institute of
Neuroscience and Mental
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Human gene 2 (H2) relaxin (henceforth referred to as ‘‘relaxin’’) is a peptide hormone composed of two
peptide chains (A and B chains) linked by two inter-chain and one intra-chain disulphide bond. Initially char-
acterized as a pregnancy hormone with species-dependent roles (Fevold et al., 1930; Bathgate et al., 2006),
relaxin has long been of interest as a therapeutic for a number of disease states including cardiovascular
(Samuel et al., 2006; Teerlink et al., 2013) and fibrotic disorders (Lekgabe et al., 2005). Around 15 years
ago, the receptor mediating the effects of relaxin was identified to be the Class A G protein-coupled re-
ceptor (GPCR) originally called LGR7 (Hsu et al., 2002), but now named relaxin family peptide receptor 1
(RXFP1). RXFP1 and the closely related RXFP2, the receptor for insulin-like peptide 3 (INSL3), are large re-
ceptors by class A GPCR standards, with an N-terminal extracellular domain (ECD) comprising approxi-
mately half of the amino acid sequence. The ECD is made up of at least three protein domains (Figure 1):
the LDLa module, linker domain, and leucine-rich repeat (LRR) domain. A thorough understanding of how
these domains combine with the transmembrane domain (TMD) to allow relaxin-RXFP1 binding and acti-
vation is necessary to rationally design new relaxin-like molecules as therapeutics.
Most Class AGPCR agonists bind directly to the TMD to promote receptor activation and subsequent intra-
cellular signaling events. Conversely, activation of RXFP1 is initiated by relaxin binding to the ECD with co-
ordinated interactions between the LDLa module, linker, and LRR domain driving activation of the TMD.
Historically it was believed that the LRR domain is the primary high-affinity relaxin-binding site in the
ECD of RXFP1 (Bullesbach and Schwabe, 2005; Scott et al., 2009) with a lower-affinity interaction in the
TMD (Halls et al., 2005). However, more recent work has demonstrated that the linker domain has an impor-
tant role in binding (Sethi et al., 2016). Relaxin can also bind to and activate the related INSL3 receptor,
RXFP2, where it binds in a fashion referred to as a hybrid mode, resembling a binding mode somewhere
between relaxin-RXFP1 and INSL3-RXFP2 (Bruell et al., 2017). However, RXFP2 lacks the helical stretch of
linker thought to bind relaxin and thus has a lower affinity for relaxin. Early work demonstrated that removal
of the LDLa module from RXFP1 completely abolished relaxin-mediated signaling but had no effect on
relaxin binding affinity (Scott et al., 2006). Site-directed mutagenesis identified key residues within the
LDLa, which are proposed to drive receptor activation by forming contacts with the first and second extra-
cellular loops of the TMD (Kong et al., 2013; Diepenhorst et al., 2014). The LDLa module is believed to be a
tethered agonist, which interacts with the TMD to promote active receptor-state conformations andiScience 11, 93–113, January 25, 2019 ª 2018 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Protein Domains of RXFP1 and RXFP2 and Representative Ligand-free and Ligand-bound RXFP1 Structures
(A) Schematic representation of the protein domains within RXFP1 and RXFP2. (B and C) Cartoon representation of the
structure of (B) the ligand-free RXFP1 receptor and (C) the relaxin-bound RXFP1 complex highlighting the coordinated
relaxin-leucine-rich repeat (LRR) and relaxin-linker interactions that are necessary to direct LDLa-linker interactions with
the transmembrane domain (TMD) that result in receptor activation. Receptor domains and H2 relaxin (green) are labeled
and colored; LDLa domain (red), linker domain (magenta), LRR domain (gray), and TMD (blue).stimulate cell signaling. More recently, it has been demonstrated that the linker domain also plays a key
role in activation such that the tethered agonist is now considered to be the combination of LDLa-linker
(Sethi et al., 2016; Bruell et al., 2013). Although this indicates some separation between the events of relaxin
binding and receptor activation, how these domains combine to form functional RXFP1 proteins has been
difficult to study.
This current model of RXFP1 activation is presented in Figure 1 and proposes that relaxin binds the ECD
concomitantly over two major sites, with residues in the relaxin B-chain forming contacts with the LRR
domain and the A-chain of relaxin potentially interacting with the linker domain. Relaxin binding subse-
quently promotes the stabilization and extension of an a-helix within the linker domain (Sethi et al.,
2016). The resultant structural rearrangement leads to the display of key residues in the LDLa, and poten-
tially the linker domain, to interact with the TMD and agonize the receptor. Recent nuclear magnetic reso-
nance (NMR) studies by our group using purified portions of the LDLa-linker domains gave an estimate of
the binding affinity (Kd) of relaxin for the linker domain of about 200 mM (Sethi et al., 2016) and therefore
predicted that the binding affinity of relaxin for the LRR domain alone must be around 1 mM to achieve
the subnanomolar affinity observed for relaxin binding to the full receptor. It has been challenging to inves-
tigate this complex mechanism of relaxin binding across multiple domains in whole cells because of limi-
tations with the traditional ligands used for binding assays, and so the relaxin binding affinity for the LRR
domain alone, for example, has not been experimentally determined.
Nanoluciferase (Nanoluc) is a bright luciferase that has gained considerable attention as a useful reporter
with a range of research applications (England et al., 2016; Hall et al., 2012). Fusing Nanoluc to the
N-termini of GPCRs and measuring bioluminescence resonance energy transfer (BRET) between Nanoluc
and a fluorescently labeled ligand (termed NanoBRET; Machleidt et al., 2015) has been proved to be an
excellent tool to investigate ligand binding to a variety of GPCRs (Wang et al., 2017; Christiansen et al.,
2016; Hansen et al., 2017; Stoddart et al., 2015; Soave et al., 2016) as well as receptor tyrosine kinases (Kil-
patrick et al., 2017a, 2017b; Peach et al., 2017). Using NanoBRET for ligand binding has numerous94 iScience 11, 93–113, January 25, 2019
advantages over traditional ligand-binding assays (Stoddart et al., 2016, 2017)—notably a very low non-
specific binding signal, no requirement for removal of unbound fluorescent ligand before measurement,
and the potential for easily performing real-time measurements for investigation of binding kinetics.
The investigation of binding kinetics to better understand themechanism by which a ligand binds its recep-
tor is an area of interest for drug discovery (Tummino and Copeland, 2008; Lu and Tonge, 2010; Swinney
et al., 2014). The simplest type of ligand:receptor interaction is the one that occurs via a single reversible





Previous reports measuring relaxin association and dissociation rates have assumed a single-step binding
mechanism to calculate on- and off-rates (Tan et al., 1999; Kocan et al., 2017) and have only used a single
concentration of radioactively labeled relaxin in association experiments, presumably due to the limita-
tions regarding the availability of labeled relaxin and the labor-intensive nature of traditional kinetic
ligand-binding assays. Thus real-time measurements of relaxin association to and dissociation from
RXFP1 using a technique such as NanoBRET would allow relatively easy kinetic discrimination between a
simple one-step bindingmechanism and amore complexmulti-step bindingmechanism, which is currently
hypothesized to be occurring.
Here, we describe the development and application of NanoBRET in live HEK293T cells using Nanoluc-
tagged RXFP1 and TAMRA-labeled relaxin (TamRLX). Using this technique, we performed NanoBRET satu-
ration binding experiments on several different Nanoluc-RXFP1 constructs in which key receptor domains
had been mutated or removed, to dissect the importance of different domains on the overall relaxin bind-
ing affinity. A key finding was that, contrary to previously published reports, removal of the N-terminal LDLa
domain does perturb relaxin binding to RXFP1. Kinetic experiments revealed complexities that were
incompatible with a single-step binding mechanism, and dissociation experiments indicated the existence
of at least two relaxin-bound states of RXFP1. To test the hypothesis that the two binding states are asso-
ciated with the binding sites in the LRR and linker domains, we tested binding to RXFP2, which does not
contain the linker-binding site (Bruell et al., 2017), and demonstrated a single-step binding mechanism.
In addition, we created chimeric receptors whereby we inserted RXFP1 linker residues into RXFP2 and
observed an improvement in both binding and signaling capacity in response to relaxin, as well as a
biphasic dissociation profile more similar to that of RXFP1 than of wild-type RXFP2. This finding was sup-
ported by data from NMR titrations with relaxin and recombinant LDLa-linker proteins, which highlighted
gain of relaxin binding to the linker region in the chimeric RXFP2 protein. Overall, these studies agree with
the hypothesized multi-step model of relaxin:RXFP1 binding/activation, highlighting how using the
NanoBRET technique that enables kinetic measurements of ligand:receptor binding can reveal subtle,
albeit important, effects to aid drug development against this important therapeutic target.RESULTS
Characterization of TamRLX and Nanoluc-RXFP1
A key aspect of this study was the synthesis of fluorescently labeled relaxin. Labeling relaxin at only one site
was important to avoid potentially confounding BRET results. The fluorescent relaxin used here was pro-
duced by solid-phase peptide synthesis, with the addition of the orange-red fluorescent dye TAMRA to
the N terminus of the A-chain of relaxin via reductive amidation. The ability of TamRLX to activate
RXFP1 was tested by using a cyclic AMP (cAMP) reporter gene assay in cells stably expressing RXFP1 (Fig-
ure 2A). TamRLX activated RXFP1 with full efficacy compared with relaxin; however, there was a slight
decrease in the potency of TamRLX at RXFP1 compared with relaxin (pEC50 = 10.06 G 0.04 for TamRLX
compared with 10.57 G 0.03 for relaxin; Table 1).
Nanoluc was tagged to the N-terminus of RXFP1 between a FLAG epitope tag and the LDLa module, and
the ability of Nanoluc-RXFP1 to signal when stimulated with relaxin was investigated using the cAMP re-
porter gene assay. Given the positioning of Nanoluc in the construct and the importance of the LDLa mod-
ule in receptor activation, this addition was well tolerated, showing only a small, albeit significant, rightward
shift of the concentration-response curve compared with RXFP1 (Figure 1C, Table 1; pEC50 of 10.71G 0.02
for RXFP1 compared with 10.46 G 0.06 for Nanoluc-RXFP1; p < 0.01). ML290 is an allosteric agonist of
RXFP1 that binds the TMD directly to activate RXFP1 (Kocan et al., 2017; Chen et al., 2013; Xiao et al.,iScience 11, 93–113, January 25, 2019 95
Figure 2. Characterization of TamRLX and Nanoluc-RXFP1 Functional Activity and Use in BRET Experiments
(A and B) Dose-response curves of cAMP activity in HEK293T cells expressing RXFP1 (A) or Nanoluc-RXFP1 (B) when
stimulated with relaxin or TamRLX using a cAMP reporter gene system. Pooled data from three to seven independent
experiments performed in triplicate.
(C and D) (C) Dose-response curves of cAMP activity in HEK293T cells transiently expressing either RXFP1 or Nanoluc-
RXFP1 and stimulated with relaxin, using cAMP reporter gene system. Pooled data from seven to nine independent
experiments performed in triplicate. (D) BRET ratio of HEK293T cells transfected with varying amounts of Nanoluc-RXFP1
DNA and incubated with either vehicle or 25 nM TamRLX (G2.5 mM relaxin). Pooled data from four independent
experiments performed in duplicate.
(E) NanoBRET saturation binding in HEK293T cells transiently expressing Nanoluc-RXFP1 and incubated with varying
concentrations of TamRLX with non-specific signal determined by co-incubation with 2.5 mM relaxin. Determination of Kd
is provided in Table 2. Pooled data from four independent experiments performed in duplicate. All error bars (where
visible) represent SEM.
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Receptor Relaxin ML290 INSL3
pEC50 Emax n pEC50 Emax n pEC50 Emax n
RXFP1 10.71 G 0.02 109 G 2.9 9 5.84 G 0.10 85.6 G 8.1 3 ND
NL-RXFP1 10.46 G 0.06a 107 G 2.1 7 5.90 G 0.04 99.2 G 5.9 7 ND
NL-RXFP1 (DLDLa) No activity 4 5.89 G 0.03 99.8 G 2.5 4 ND
NL-RXFP1 (DLDLa/DLinker) No activity 3 5.58 G 0.02 78.6 G 4.4 3 ND
NL-RXFP1-F54A/Y58A 9.57 G 0.10b 104 G 8.4 3 5.75 G 0.40 99.0 G 7.4 3 ND
NL-RXFP1-E277Q/D279N No activity 3 5.49 G 0.09 90.3 G 15 3 ND
RXFP2 8.57 G 0.26b 90.1 G 5.4 3 ND 10.78 G 0.12 100 3
Nanoluc-RXFP2 8.36 G 0.12b 99.8 G 9.5 3 ND ND ND
ExLink1 9.48 G 0.36a,c 97.2 G 37.8 4 ND 10.15 G 0.15 114.7 G 7.47 3
ExLink2 9.74 G 0.24a,d 115 G 27.3 6 ND 10.94 G 0.16 115 G 5.45 3
Table 1. Summary of Ligand-Induced cAMP Responses of RXFP1 and RXFP2 Receptors Expressed in HEK293T Cells Utilized in These Studies
NL, Nanoluc; ND, not determined.
ap< 0.01.
bp < 0.001 versus RXFP1.
cp < 0.05.
dp < 0.01 versus RXFP2.2013; Huang et al., 2015). Critically, ML290 was able to activate RXFP1 and Nanoluc-RXFP1 with the same
potency and efficacy (Table 1). Finally, the combination of TamRLX and Nanoluc-RXFP1 was tested (Fig-
ure 2B), showing that TamRLX activates the Nluc-RXFP1 with full efficacy compared with relaxin; however,
there was again a small decrease in the potency of TamRLX at Nluc-RXFP1 (pEC50 = 9.77G 0.07), similar to
that seen for TamRLX activation of RXFP1. Nonetheless, the sub-nanomolar potency of TamRLX validated
the peptide as a suitable fluorescent ligand for RXFP1 binding studies.
The expression of Nanoluc-RXFP1 was varied by titrating HEK293T cells with varying amounts of Nanoluc-
RXFP1-encoding plasmid in transient transfections. Transfected cells were then incubated at room temper-
ature for 90 min with either vehicle or 25 nM TamRLX (with or without 2.5 mM unlabeled relaxin) before
adding Nano-Glo (Nanoluc luciferase substrate) to determine if a BRET signal could be detected between
Nanoluc and TAMRA. Binding of TamRLX toNanoluc-RXFP1 produced a strong BRET signal with negligible
non-specific binding signal, and we found that the highest NanoBRET binding signal was produced with
the lowest expression levels (Figure 2D), and thus used lower transfection levels (10–30 ng/well) for all sub-
sequent NanoBRET experiments.
We then performed a saturation binding experiment by incubating varying concentrations of TamRLX
(0–25 nM) with Nanoluc-RXFP1-expressing HEK293T cells and determined non-specific signal by co-incu-
bation with an excess of unlabelled relaxin. This yielded an excellent quality of fit to a one-site binding
isotherm (Figure 2E; Kd = 0.42 G 0.03 nM), in line with that previously reported in the literature (Halls
et al., 2005; Shabanpoor et al., 2012; Sethi et al., 2016).
NanoBRET Saturation Binding Assays to Investigate the Multiple Binding Domains of RXFP1
Relaxin is believed to bind to the ECD of RXFP1 simultaneously across two distinct domains: the LRR and
linker domains. We therefore cloned several different mutant and chimeric Nanoluc-RXFP1 constructs,
which were rationally chosen to dissect the importance of these key domains for overall relaxin binding af-
finity. Importantly, all the RXFP1 mutant receptors demonstrated no changes in ligand potency or efficacy
of the small molecule allosteric agonist ML290, highlighting that the receptors were able to couple to G
protein and were expressed at the cell surface normally (Table 1).
The primary high-affinity binding interaction between relaxin and RXFP1 is believed to be between arginine
residues B13 and B17 in the relaxin B-chain, which form ionic interactions with acidic residues E277/D279iScience 11, 93–113, January 25, 2019 97
Figure 3. NanoBRET Saturation Binding on RXFP1 and ECD-Only Constructs
Hek293T cells transiently expressing Nanoluc-tagged constructs (A) Nanoluc-RXFP1(E277Q/D279N), (B) Nanoluc-
ECD(E277Q/D279N), (C) Nanoluc-RXFP1(ΔLDLa/ΔLinker), (D) Nanoluc-ECD(ΔLDLa/ΔLinker), (E) Nanoluc-RXFP1(F54A/
Y58A), (F) Nanoluc-ECD(F54A/Y58A) incubated with varying concentrations of TamRLX with non-specific signal
determined by co-incubation an excess of unlabelled relaxin.and D231/E233 in the LRR domain of RXFP1, respectively (Bullesbach and Schwabe, 2005). We found
that mutating just one of these pairs of acidic residues (Nanoluc-RXFP1-E277Q/D279N) was enough
to abolish any detectable TamRLX binding up to a concentration of 500 nM (Figure 3A). This lack of
binding was associated with no cAMP activity in response to relaxin (Table 1). Interestingly, when we
applied this mutation to a construct encoding only the ECD of RXFP1 attached to a membrane anchor (pre-
viously termed 7BP; Hsu et al., 2002), TamRLX was able to bind with reasonable affinity (Figure 3B;
Kd = 136 G 10 nM).
Using the ECD-only construct and removing the LDLa/linker domains (Nanoluc-ECD [DLDLa/DLinker]), we
were able to estimate the binding affinity of TamRLX for the LRR domain alone to be 121 G 5.9 nM (Fig-
ure 3D). When the TMD was reintroduced (Nanoluc-RXFP1(DLDLa/DLinker)) the affinity for TamRLX was
improved (Figure 3C; Kd = 58 G 13 nM).
We also applied a previously characterized linker domain mutation, F54A/Y58A, which results in a 10-fold
decrease in both relaxin binding and activation (Sethi et al., 2016). In our NanoBRET saturation binding
studies, TamRLX also exhibited a 10-fold reduction in binding to Nanoluc-RXFP1-F54A/Y58A (Figure 3E;
Kd = 5.8 G 0.28 nM) compared with Nanoluc-RXFP1. Conversely, the affinity of TamRLX for the ECD-
only construct with this mutation (Figure 3F; Kd = 0.34 G 0.01 nM) was not different from its affinity for
Nanoluc-ECD (Figure 4B; Kd = 0.28 G 0.01 nM).98 iScience 11, 93–113, January 25, 2019
Figure 4. NanoBRET Saturation Binding on RXFP1 and ECD-Only Constructs Lacking the LDLa Domain
Hek293T cells transiently expressing Nanoluc-tagged constructs (A) Nanoluc-RXFP1(ΔLDLa), (B) Nanoluc-ECD, (C)
Nanoluc-ECD(ΔLDLa/ΔLinker) incubated with varying concentrations of TamRLX with non-specific signal determined by
co-incubation 2.5 mM relaxin.NanoBRET Saturation Binding Assays to Probe the Role of the LDLa on Relaxin Binding
Studies have clearly shown that relaxin does not have direct binding interactions with the LDLa (Hopkins
et al., 2007; Sethi et al., 2016), and removing or altering the LDLa module from RXFP1 does not appear
to affect the relaxin binding affinity (Scott et al., 2006; Hopkins et al., 2007; Kong et al., 2013). We were
therefore surprised to observe a statistically significant reduction in the affinity of TamRLX for RXFP1
with the LDLa module deleted (Figure 4; Table 2; Kd = 0.42 G 0.03 nM for Nanoluc-RXFP1 versus Kd =
1.10 G 0.09 nM for Nanoluc-RXFP1(DLDLa); p < 0.001).
TamRLX binding affinity for the ECD-only version of these constructs were similarly decreased (Figures 4B
and 4C; Kd = 0.28 G 0.013 nM for Nanoluc-ECD versus Kd = 1.1 G 0.13 nM for Nanoluc-ECD(DLDLa);
p < 0.001). This suggests that the LDLa plays a subtle role in modulating how relaxin binds to the LRRs
and linker domain, which is independent of potential interactions with the TMD.
The results on RXFP1-ECD constructs suggest that the lack of TMD, and therefore lack of G protein
coupling, has no influence on the relaxin binding affinity. However, there are some distinct differences in
the binding of relaxin to the ECD constructs, hence we wanted to clearly demonstrate that G protein
coupling has no influence on the relaxin binding affinity. We therefore performed the same saturation bind-
ing assays in both HEK293T cells and a HEK293 cell line in which the Gas subunit had been knocked out
(HEK293A DGas; Stallaert et al., 2017) at a physiological temperature (37
C). At this temperature, we found
that the relaxin binding affinity for Nanoluc-RXFP1 decreased compared with that at room temperature,
but that LDLa removal also resulted in similarly small decreases in TamRLX binding affinity (Figures 5A
and 5B; Kd = 3.20 G 0.02 nM for Nanoluc-RXFP1 versus Kd = 5.8 G 1.2 nM for Nanoluc-RXFP1(DLDLa)).
This was also true in the HEK293A DGas knockout cells (Figures 5C and 5D), and there were no significant
differences in TamRLX binding affinity between cell types. This further supported the notion that the subtle
decrease in relaxin binding affinity when the LDLa was removed was due to interactions at the level of the
ECD rather than related to LDLa interactions activating the TMD.
NanoBRET Association Assays to Investigate the Influence of the LDLa Module on the
Kinetics of Relaxin Binding to RXFP1
An advantage of NanoBRET compared with traditional ligand binding assays is the possibility to perform
real-time measurements of ligand binding kinetics. Measuring the rates of ligand association and dissoci-
ation directly can provide valuable insight into binding mechanisms, which may be obscured when relying
on binding measurements obtained at equilibrium. Identification of subtle differences in TamRLX binding
may provide insight into the hypothesized mechanism of RXFP1 binding, so we looked more closely at the
TamRLX binding kinetics at Nanoluc-RXFP1 and Nanoluc-RXFP1(DLDLa).
Association assays were performed using TamRLX concentrations ranging between 0.25 and 5 nM (Fig-
ure 6A). The association profiles fit well to one-phase exponential functions, which gave pseudo-first-order
association rates (kobs). Based on the assumption that this binding occurs via a single-step mechanism, kobs
is related to the concentration of TamRLX ([TamRLX]) by Equation 2.
kobs = kon½TamRLX+ koff (Equation 2)iScience 11, 93–113, January 25, 2019 99









RXFP1 0.42 G 0.03 (4) 3.2 G 0.3 (3) 2.3 G 0.1 (3)
RXFP1 (DLDLa) 1.1 G 0.09 (3)a 5.0 G 0.2 (3)b 5.8 G 0.5 (3)c
RXFP1 (DLDLa/DLinker) 58 G 13 (3)a – –
RXFP1-E277Q/D279N No binding – –
RXFP1-F54A/Y58A 5.4 G 0.3 (3)a – –
ECD 0.28 G 0.01 (3) – –
ECD (DLDLa) 1.1 G 0.13 (3)d – –
ECD (DLDLa/DLinker) 121 G 5.9 (3)d – –
ECD-E277Q/D279N 136 G 10 (3)d – –
ECD-F54A/Y58A 0.34 G 0.01 (3) – –
RXFP2 10.74 G 1.64 (4) – –
ExLink1 2.74 G 0.52 (4) e – –
ExLink2 1.17 G 0.2 (4) e – –
Table 2. Summary of NanoBRET Saturation Binding Kd Determinations for the Nanoluc-Tagged Receptors Used in
This Study
The number of experimental replicates for each individual construct are shown in parentheses.
ap< 0.001 versus Nanoluc-RXFP1.
bp< 0.01 versus Nanoluc-RXFP1 in HEK293T cells at 37C.
cp< 0.001 versus Nanoluc-RXFP1 in HEK293A DGas cells at 37
C.
dp< 0.001 versus Nanoluc-ECD.
ep< 0.0001 compared with Nanoluc-RXFP2.Compatible with this assumption, the kobs versus TamRLX concentration plot showed a linear relationship
(Figure 6B), allowing determination of kon and koff by linear regression (Table 3). The calculated koff and kon
for TamRLX at Nanoluc-RXFP1 was 0.054 G 0.009 min1 and 0.046 G 0.004 nM1.min1, respectively.
Comparatively, the binding of TamRLX to Nanoluc-RXFP1(DLDLa) showed differences in both on- and
off-rates (kon= 0.026 G 0.005 nM
1.min1; koff = 0.249 G 0.012 min
1), which is consistent with the lower
binding affinity seen in saturation binding experiments.
The calculated Kd (= koff/kon) from these association experiments were 1.2 G 0.23 nM for TamRLX at
Nanoluc-RXFP1 and 9.6 G 1.8 nM at Nanoluc-RXFP1(DLDLa). If the assumption of a one-step binding
mechanism is valid, these results should closely match those observed in equilibrium saturation binding
assays; however, the calculated Kd for TamRLX at Nanoluc-RXFP1(DLDLa) was almost 10-fold different
from that obtained in saturation binding. Additionally, the finding that TamRLX has a lower kon at
Nanoluc-RXFP1(DLDLa) was unexpected because on-rates are usually linked to the diffusional characteris-
tics of the ligand, which remained constant. These inconsistencies suggest that the assumption of a one-
step binding mechanism is invalid, providing support for a more complex binding mode.NanoBRET Dissociation Assays to Investigate the Influence of the LDLa Module on the
Kinetics of Relaxin Binding to RXFP1
Owing to the presence of two binding sites, we hypothesized that relaxin binding and activation of RXFP1
involves at least two steps. Thus it is reasonable to suggest that the dissociation profile of relaxin from
RXFP1 may show at least two distinct phases, indicative of at least two relaxin-bound states at the receptor.
Previous studies that have measured relaxin dissociation from RXFP1 have generally fit dissociation curves
to one-phase decay functions; however, we speculated that the sensitivity and superior temporal resolution
afforded by the NanoBRET system might allow reliable detection and quantitation of multiple off-rates.100 iScience 11, 93–113, January 25, 2019
Figure 5. NanoBRET Saturation Binding at 37C in Hek293T and Hek293AdelGas
Cells transiently expressing Nanoluc-RXFP1 (A and C) or Nanoluc-RXFP1(DLDLa) (B and D) were incubated at 37C with
varying concentrations of TamRLX with non-specific signal determined by co-incubation 2.5 mM relaxin. A comparison was
made between receptor expression in Hek293T (A and B) and Hek293AdelGas (C and D). Pooled data from three
independent experiments performed in duplicate. All error bars (where visible) represent SEM. All Kd determinations are
provided in Table 2.Dissociation experiments were performed at room temperature in HEK293T cells expressing Nanoluc-
tagged receptors and involved binding 1 nM TamRLX to equilibrium for 1 hr, followed by removal of un-
bound TamRLX from the well and addition of 10 mM unlabeled relaxin. The BRET ratios were normalized
to wells containing vehicle only (0%) and wells in which 1 nM TamRLX remained (100%). This was done to
remove the potentially confounding effect of BRET signal decay, which was evident over long time periods
(Figure S1).
TamRLX dissociated from Nanoluc-RXFP1 more slowly than from Nanoluc-RXFP1(DLDLa) (Figure 7A). Both
dissociation profiles were found to fit best to a two-phase exponential decay function, as can be seen in the
time-invariant distribution of residuals for the two-phase models (Figures 7B–7E). The fast and slow off-rate
estimates were the same for both constructs (Table 3; koffFAST = 0.15 G 0.05 min
1, koffSLOW = 0.021 G
0.003 min1 for Nanoluc-RXFP1; koffFAST = 0.16 G 0.02 min
1, koffSLOW = 0.026 G 0.009 min
1 for
Nanoluc-RXFP1(DLDLa)). The overall slower dissociation from Nanoluc-RXFP1 can be explained by it hav-
ing a lower proportion of the fast dissociation component (around 19% for Nanoluc-RXFP1 compared with
61% for Nanoluc-RXFP1(DLDLa)). This suggested that the same two relaxin-bound states can exist when the
LDLa domain is removed and that the LDLa may help to stabilize the higher affinity-bound state.NanoBRET Dissociation Assays at 37C to Further Validate the Role of the LDLa in Relaxin
Binding Interactions with the ECD
The physiological relevance of two relaxin-bound states was further investigated by obtaining TamRLX
dissociation profiles at 37C (Figure 8). Dissociation was initiated by automated injection of a 1,000-fold
excess of unlabeled relaxin to accurately capture the expected faster dissociation at a higher temperature
rather than by manual handling of the plate to remove unbound TamRLX. This was deemed suitable as
there was no difference in TamRLX off-rates at room temperature when 10 mMunlabeled competitor relaxin
was added, regardless of whether unbound TamRLX was removed or not (Figure S2). Here, the TamRLX
dissociation from Nanoluc-RXFP1 again fit best to a two-phase exponential decay (Table 3; koff FAST =
0.19G 0.01 min1; koff SLOW = 0.044G 0.008 min
1); however, the faster off-rate accounted for a larger per-
centage of the overall dissociation profile (around 67% at 37C compared with 20% at room temperature).
The dissociation of TamRLX from Nanoluc-RXFP1(DLDLa) was clearly faster compared with that from
Nanoluc-RXFP1 (Figure 8A); however, we fit the data to a one-phase exponential as a two-phase exponen-
tial did not improve the quality of the fit. Interestingly, this monophasic off-rate for Nanoluc-RXFP1(DLDLa)iScience 11, 93–113, January 25, 2019 101
Figure 6. NanoBRET Association Experiments in Nanoluc-Receptor-Expressing HEK293T Cells
(A) Representative figure of a single experiment with HEK293T cells transiently expressing Nanoluc-RXFP1 and treated
with varying concentrations of TamRLX. Curves fit to a one-phase association equation in GraphPad Prism to obtain kobs
values. Experiments performed in triplicate, and error bars represent SEM.
(B) Pooled kobs from three independent association experiments for Nanoluc-RXFP1 and Nanoluc-RXFP1(DLDLa), plotted
as a function of TamRLX concentration and fit to a linear regression in GraphPad Prism. Dotted line indicates 95%
confidence interval of the linear regression, and each point represents a single kobs determination from one
experiment. On- and off-rate determinations from linear fit are provided in Table 3, based on the relationship kobs =
kon.[TamRLX] + koff.was 0.20 G 0.004 min1, corresponding to the fast off-rate for TamRLX dissociation from Nanoluc-RXFP1.
Additionally, the residuals plots for both fits used (two phase for RXFP1, Figure 8D; one phase for
RXFP1(DLDLa), Figure 8C) show movement above and below the line in the first 10 min of dissociation,
which may indicate additional complexity that was not fit by these models.
NanoBRET Saturation Binding Assays to Investigate the Binding of Relaxin to RXFP2 and
Chimeric Linker Insertion Mutants
To test the hypothesis that the two binding states of RXFP1 are associated with the binding sites in the LRRs
and the linker domain, we conducted binding studies on RXFP2, which does not contain the linker-binding
site (Bruell et al., 2017). We therefore first cloned a Nanoluc tag at an equivalent position of FLAG-tagged
RXFP2 to Nanoluc-RXFP1, and the resulting Nanoluc-RXFP2 construct was tested for cAMP activity in
response to relaxin in the same way (Figure 9A). Relaxin potency at Nanoluc-RXFP2 was not significantly
different from RXFP2 (Table 1), and similarly, the potency of TamRLX was not significantly different from
relaxin at RXFP2 (Figure 9B; EC50 = 8.46 G 0.25 versus 8.57 G 0.26). We previously reported the affinity
of relaxin for RXFP2 as being around 10 nM using a saturation binding assay with europium-labeled H2
relaxin (Bruell et al., 2017). Similarly, here using the NanoBRET system with Nanoluc-RXFP2 titrated with
TamRLX, we demonstrated that the Kd was 10.74 G 1.64 nM (Figure 9C).
To further highlight the role of the linker-binding site, we created chimeric receptors whereby we inserted
four or seven residues from the proposed RXFP1-relaxin-binding site (Sethi et al., 2016) into the RXFP2
linker to produce the chimeras named Nanoluc-ExLink1 (four-residue insertion) and Nanoluc-ExLink2
(seven-residue insertion; Figure 10A). Both Nanoluc tagged and non-tagged versions of the constructs
were cloned for testing of TamRLX saturation binding and relaxin cAMP potency, respectively. Both
chimeric constructs showed a significantly increased affinity for TamRLX in NanoBRET saturation binding
assays (Figures 10C and 10D; Table 2; p<0.0001 compared with RXFP2 for both). This improved affinity
was matched with significantly increased potency of relaxin at both receptors compared with RXFP2 (Fig-
ure 10B; Table 1; p < 0.05 and p < 0.01 versus RXFP2, respectively). Importantly, both chimeric constructs
responded normally to the RXFP2 cognate ligand INSL3, which is known to not bind to the linker site (Bruell
et al., 2017) (Figure 10C; Table 1). The results support the notion of an additional relaxin-binding site being
present in the RXFP1, but not in the RXFP2 linker.
NanoBRET Dissociation Assays to Compare the Kinetics of Relaxin Binding to RXFP2 with
RXFP1
Given that the linker residues joining the LDLa module to the LRRs are a major point of difference between
the highly similar RXFP1 and RXFP2 receptors, we compared the TamRLX dissociation profile of the RXFP2
and the ExLink chimeric receptors (Figure 11). TamRLX dissociation from Nluc-RXFP2 was best fit to a one-
phase exponential (koff = 0.43 G 0.05 min
1; Figures 11A, 11C, and 11F), indicative of a single binding site
for relaxin in the RXFP2 LRRs. Introduction of the RXFP1-linker-binding site in the ExLink1 and ExLink2102 iScience 11, 93–113, January 25, 2019
NL-Tagged Receptor Association Experiments Dissociation Experiments Dissociation Experiments (37C)
kon (nM.min
1) koff (min












RXFP1 0.046 G 0.004 0.054 G 0.009 1.2 G 0.23 0.15 G 0.05 0.021 G 0.003 G 4 0.19 G 0.01 0.044 G 0.008 67 G 5
RXFP1 (DLDLa) 0.026 G0.005 0.25 G0.01 9.6 G1.8 0.16 G0.02 0.026 G0.009 G 6 a0.20 G0.004 – –
RXFP2 – – – a0.43 G 0.05 – – – –
ExLink1 – – – 0.46 G 0.05 0.04 G 0.01 G 1 – – –
ExLink2 – – – 0.47 G 0.09 0.085 G 0.03 G 12 – – –
Table 3. Pooled Kinetic Parameters from NanoBRET Kinetic Experiments in HEK293T Cells
Rate constant determinations from RXFP1 association experiments (Figure 5), RXFP1 dissociation experiments (Figure 6), RX 1 dissociation experiments at 37C (Figure 7), and RXFP2 dissociation exper-
iments (Figure 11).
NL, Nanoluc.



































Figure 7. NanoBRET Dissociation Experiments at Room Temperature
(A) HEK293T cells transiently expressing Nanoluc-tagged receptors (RXFP1 in blue and RXFP1(DLDLa) in red) were
incubated to equilibrium with 1 nM TamRLX before initiation of dissociation by removal of unbound TamRLX and addition
of 10 mM unlabeled relaxin. Data are pooled from four to five independent experiments and fit to a two-phase decay
equation. Error bars represent SEM. Mean residuals for one-phase decay fits (B and C) or two-phase decay fits (D and E)
are also shown. Rate constant determinations from two-phase decay fits are provided in Table 3.receptors resulted in TamRLX dissociation profiles that were best fit by a two-phase exponential (Figures
11B, 11D, 11E, 11G, and 11H). The fast off-rate for the ExLink receptors (0.46 G 0.05 min1 for ExLink1 and
0.47 G 0.09 min1 for ExLink2) closely matched the monophasic of rate observed for RXFP2, suggesting
that the fast component relates to relaxin binding interactions with the LRRs. In addition, the percentage
of fast component decreased as the linker length increased (79.01% G 0.85% fast for ExLink1; 49.43% G
11.8% fast for ExLink2), approaching the levels seen for RXFP1. The data suggest that the dissociation of
relaxin from RXFP2 occurs in a simple, one-step fashion but that the insertion of a secondary binding
site alters the kinetic profile to resemble that seen in RXFP1.NMR Titrations of Relaxin with LDLa-Linker Proteins
We have previously designed and characterized the recombinant LDLa-linker constructs, RXFP1(1-72) (Sethi
et al., 2016) and RXFP2(1-65) (Bruell et al., 2017) and investigated their interaction with relaxin using solution
NMR spectroscopy and performing relaxin titrations monitored by 2D 1H-15N Heteronuclear Single Quantum
Coherence (HSQC). For RXFP1(1-72), residues within the linker region (Asp51, Ala55, Tyr57, and Thr61) showed
significant chemical shift differences (Figure 12A), whereas for RXFP2(1-65), residues within the LDLa module
(Cys26, Asp30, andGlu38) and Asp43 from theN-terminal end of the linker region showedmajor chemical shift
perturbations (Figure 12B), albeit weaker than those of RXFP1(1-72). By inserting the proposed relaxin-binding
region from RXFP1(1-72) into RXFP2(1-65), thus creating the chimera RXFP2(1-65)-ExLink, we were able to confirm
that the interaction surface was shifted away from the LDLa module and into the extended linker as demon-
strated by the significant chemical shift perturbations of linker residues Ile50, Thr60, and Ala65 (Figure 12C).
Importantly, no residues within the LDLa module of RXFP2(1-65)-ExLink show significant chemical shift differ-
ences. Fitting these differences of Ile50, Thr60, and Ala65 to a single-site binding curve shows the affinity of
relaxin for RXFP2(1-65)-ExLink is 187 G 7 mM (compared with 330 G 10 mM for RXFP2(1-65); Bruell et al., 2017;104 iScience 11, 93–113, January 25, 2019
Figure 8. NanoBRET Dissociation Experiments at 37C
(A) HEK293T cells transiently expressing Nanoluc-tagged receptors (RXFP1 in blue and RXFP1(DLDLa) in red) were
incubated to equilibrium with 5 nM TamRLX before initiation of dissociation by injection of unlabeled relaxin to a
concentration of 5 mM. Data are pooled from five independent experiments and fit to a two-phase decay equation
(Nanoluc-RXFP1) or one-phase decay equation (Nanoluc-RXFP1(DLDLa)). Error bars represent SEM. Mean residuals for
one-phase decay fits (B and D) or two-phase decay fits (C and E) are also shown. Rate constant determinations from two-
phase decay fit (Nanoluc-RXFP1) or one-phase decay fit (Nanoluc-RXFP1(DLDLa)) are provided in Table 3.Figure S4), suggesting a significant gain in the relaxin binding affinity for the extended RXFP2 linker. This
further supports the idea that the RXFP1 linker plays a pivotal role in the binding of relaxin.DISCUSSION
Relaxin activates RXFP1 through interactions with multiple domains in the ECD of RXFP1. However, the
exact mechanism by which these domains combine to agonize the receptor has been difficult to establish.
The current multi-step model of RXFP1 activation hypothesizes that a conformational rearrangement in the
ECD of RXFP1 upon relaxin binding drives LDLa/linker-TMD interactions to activate the receptor. Recent
NMR studies have shown that relaxin interacts with the linker domain to promote the extension of a helix
within the linker (Sethi et al., 2016), and this piece of information has been key in mechanistically bridging
the connection between relaxin binding (predicted to be predominantly in the LRR domain) and activation
of the TMD via the LDLa-linker. These experiments, however, were performed using purified fragments of
the ECD and relaxin. Indeed, the proposed multi-step mechanism is a supposition based on knowledge of
the complex nature of relaxin:RXFP1 binding interactions—kinetic evidence was lacking. We therefore
sought a facile and sensitive assay system in which to investigate relaxin binding kinetics in whole cells
to test a single-step model (hence indirectly supporting or invalidating a multi-step model), and thus suc-
cessfully established a NanoBRET-based binding technique in live HEK293T cells in a 96-well-plate-based
format. Addition of tags (Nanoluc on RXFP1 N terminus and TAMRA on relaxin) was well tolerated, and
NanoBRET saturation binding experiments produced TamRLX binding Kd of 0.42G 0.03 nM. This is consis-
tent with published affinities from traditional fluorescence-intensity-based approaches using europium-
labeled relaxin (Shabanpoor et al., 2012) or radiolabeled relaxin (Halls et al., 2005), however, with theiScience 11, 93–113, January 25, 2019 105
Figure 9. Characterization of TamRLX and Nanoluc-RXFP2 and NanoBRET Saturation Binding
(A) Dose-response curves of cAMP activity in HEK293T cells expressing RXFP2 when stimulated with relaxin or TamRLX.
Pooled data from two to three independent experiments performed in triplicate.
(B) Dose-response curves of cAMP activity in HEK293T cells transiently expressing either RXFP2 or Nanoluc-RXFP2 and
stimulated with relaxin, using cAMP reporter gene system. Pooled data from three independent experiments performed
in triplicate.
(C) TamRLX saturation binding in HEK293T cells transiently expressing Nanoluc-RXFP2. Pooled data from three
independent experiments performed in duplicate. All error bars (where visible) represent SEM. All Kd determinations are
provided in Table 2.notable advantage that these experiments do not require the removal of unbound labeled relaxin and have
minimal non-specific signal.
It is counterintuitive that lower expression levels provided the best NanoBRET binding signal (Figure 2D);
however, this can be explained by our observation that that RXFP1 (like many GPCRs) appears to accumu-
late significantly within intracellular compartments when overexpressed, presumably due to overwhelming
the receptor trafficking machinery of the cell. As BRET is a ratiometric measurement, accumulation of intra-
cellular receptor that cannot bind ligand would decrease the NanoBRET binding signal accordingly, hence
the lowest expression (allowing the greatest proportion of receptor to traffic to the cell surface) is
preferred. This should be seen as a great strength of NanoBRET measurements of ligand binding as the
brightness of Nanoluc combined with the ratiometric nature of BRET means that lower levels of expression
are actually preferable (resulting in less intracellular accumulation and improved signal:noise assay perfor-
mance), contrasting with traditional radioligand binding assays wherein supraphysiological expression
levels are often required to obtain a sufficiently strong signal.
Initially, we performed TamRLX saturation binding experiments on Nanoluc-RXFP1 constructs in which key
domains had been removed or mutated. The current model of relaxin binding suggests that relaxin binds
concomitantly across two sites, the LRR domain and the linker domain. The affinity of the LRR domain has
been estimated to be around 1 mM, a rough calculation based on the affinity for the linker domain alone
(approximately 200 mM) and for the full-length receptor (approximately 1 nM). Using NanoBRET, we
measured the affinity of TamRLX to be 121 G 5.9 nM for the LRR domain attached to a membrane anchor106 iScience 11, 93–113, January 25, 2019
Figure 10. Comparison of Extended Linker (ExLink) Constructs with RXFP1 and RXFP2
(A) Sequence alignment of RXFP1 and RXFP2 linkers, followed by ExLink1 with inserted residues shown in green and
ExLink2 with inserted residues in blue.
(B and C) cAMP activity data comparing RXFP1 and RXFP2 with ExLink constructs in response to (B) relaxin and (C) INSL3.
HEK293T cells transiently expressing constructs incubated with varying concentrations of ligand. Pooled data from at
least three independent experiments performed in triplicate. All Emax and pEC50 determinations are provided in Table 1.
(D and E) TamRLX saturation binding in HEK293T cells transiently expressing (D) Nanoluc-ExLink1 and (E) Nanoluc-
ExLink2 compared with Nanoluc-RXFP2. Pooled data from three independent experiments performed in duplicate. All Kd
determinations are provided in Table 2. All error bars (where visible) represent SEM.(Figure 4D), or 58G 13 nMwhen attached to the RXFP1 TMD (Figure 4C). The exoloops of RXFP1 have been
demonstrated to potentially comprise an additional relaxin-binding site (Diepenhorst et al., 2014; Halls
et al., 2005); however, these results indicate that this site does not contribute significantly to relaxin binding
affinity. Conversely, the linker domain is a significant contributor to relaxin binding affinity, as when the
linker and LRR domains are present together, there is a 50- to 100-fold improvement in relaxin binding af-
finity compared with the LRR domain alone.
We showed that mutation of key relaxin-binding residues in LRR8 (E277Q/D279N) was sufficient to
completely abolish detectable TamRLX binding and that weak binding could be restored when this muta-
tion was applied to an ECD-only construct. This suggests that remaining known relaxin interactions within
the ectodomain may be inaccessible when the LDLa/linker domains form contacts with the TMD, thus
removal of the TMDmight ‘‘open’’ the ECD to form an unnatural binding mode for relaxin. It also indicates
that the LRR domain interactions are critically involved in the initial step of relaxin binding to RXFP1.
Another important difference between full-length and ECD-only RXFP1 constructs was the effect of the
F54A/Y58A linker domain mutation, which resulted in a 10-fold decrease in TamRLX binding affinity to
the full-length receptor but did not change binding affinity for the ECD-only construct. It is difficult to
explain this observation, but it again suggests that there is an unnatural binding mode for relaxin on the
ECD-only construct of RXFP1.
Differences in the bindingmode of full-length RXFP1 compared with ECD-only RXFP1 constructs have been
noted before from observations that INSL3 (cognate peptide ligand for the related RXFP2 receptor) binds
with high affinity to the ECD-only construct of RXFP1, but only with weak affinity to full-length RXFP1 (HallsiScience 11, 93–113, January 25, 2019 107
Figure 11. NanoBRET Dissociation Experiments at Room Temperature
(A and B) HEK293T cells transiently expressing Nanoluc-tagged receptors (RXFP2 in black, ExLink1 in green, and ExLink2
in teal) were incubated to equilibrium with 13 nM TamRLX before initiation of dissociation by addition of 10 mM unlabeled
relaxin. Data are pooled from 4–12 independent experiments and fit to a one-phase decay equation (RXFP2) or two-
phase decay equation (ExLink1 and ExLink2). Error bars represent SEM. Mean residuals for one-phase decay fits (C–E)
or two-phase decay fits (F–H) are also shown. Rate constant determinations from fits are provided in Table 3.et al., 2005; Scott et al., 2012). Representations of RXFP1 have often depicted the ECD in an ‘‘open’’ config-
uration, with the LDLa domain floating unconstrained in the extracellular space until a relaxin-binding
event triggers interaction of the LDLa with the TMD. Published descriptions of the relaxin binding and
LDLa activation events still allude to relaxin binding being responsible for driving the LDLa to interact
with the TMD (Summers, 2017). The idea of relaxin initiating a movement of the LDLa toward the
TMD comes from previous studies that suggested a low-affinity binding site for relaxin in ECL2 of the
TMD (Halls et al., 2005; Diepenhorst et al., 2014). Thus the logical thought was that high-affinity relaxin
binding to the LRR domain was followed by the lower affinity interactions in ECL2, thereby bringing the
LDLa into contact with the TMD. This would be analogous to the general mechanism of peptide binding
in Class B GPCRs, where the C terminus of the peptide ligand forms an initial complex with the ECD,
followed by the N terminus of the peptide ligand interacting with the TMD to activate the receptor (Hol-
lenstein et al., 2014). However, more recently, Sethi et al. (2016) elegantly showed interactions of the
LDLa/linker with the ECL2 in the absence of relaxin, suggesting a degree of constitutive interaction.
Given the current lack of published structures for RXFP1, the known interactions of the LDLa/linker
with the extracellular loops in the absence of relaxin, and the observations provided here, it may be
more appropriate to visualize the ECD in a perpetually ‘‘closed’’ configuration in which relaxin binding
drives specific conformational rearrangements within the ECD allowing the LDLa-linker to activate the
TMD.
An unexpected finding in saturation binding experiments was that removal of the LDLa module slightly
decreased relaxin binding affinity, contrary to previous reports that relaxin binding is unaffected by
LDLa removal (Scott et al., 2006; Kong et al., 2013; Hopkins et al., 2007). Interestingly, this difference
was also evident in ECD-only constructs, as well as at 37C and in HEK293 cells lacking Gas, suggesting108 iScience 11, 93–113, January 25, 2019
Figure 12. NMR Titrations
Plot of change in average 1HN and 15N chemical shifts following titration of relaxin into (A) 15N-RXFP1(1-72), (B)
15N-
RXFP2(1-65), and (C)
15N-RXFP2(1-65)-ExLink. Residues with the greatest change are labeled above. Full HSQC spectra are
shown in Figure S5.that LDLa interactions to activate the TMD are not responsible for this subtle change. The differing re-
sults here are likely due to the increased sensitivity provided by the NanoBRET system—experimental
error using more traditional techniques could obscure such subtle differences. As the LDLa domain
has been shown to not have any direct binding interactions with relaxin (Sethi et al., 2016; Hopkins
et al., 2007), it may be that the LDLa domain has uncharacterized interactions with relaxin-binding sites
in the LRR module and/or linker domain, which modulate how relaxin interacts with these sites. Indeed,
previous NMR experiments using purified LDLa/linker from RXFP2 saw heterogeneity in resonances,
which were suspected to be caused by the linker domain ‘‘wrapping’’ back toward the N terminus of
the LDLa (Bruell et al., 2017). It may be possible that the linker folds back over the LDLa module
in RXFP1, and so relaxin interactions with the linker domain would be subtly affected by removal of
the LDLa.
An important reason for developing the NanoBRET binding assay was to perform real-time measure-
ments of relaxin association to and dissociation from RXFP1. Association assays followed the binding
of TamRLX to Nanoluc-RXFP1 (with or without LDLa module) in real time and were analyzed based on
the assumption of a single-step binding mechanism. This assumption appeared valid at first, as there
was a good linear relationship between the observed rate of association (kobs) and the concentration
of TamRLX. This provided on- and off-rates for what would seemingly be a simple bimolecular interac-
tion. The key interpretative aspect of these association experiments was that the Kd calculated from
on- and off-rates should closely match those obtained in equilibrium saturation binding assays, provided
a single-step binding mechanism is valid. However, this was not true. For Nanoluc-RXFP1, the Kd from
association experiments was 1.2 nM compared with 0.42 nM in equilibrium saturation binding experi-
ments, which, admittedly, is close enough to be considered the ‘‘same’’ when considering the magnitude
of experimental error that is expected. However, there was an almost 10-fold difference when the LDLa
was deleted (1.1 nM in equilibrium saturation binding experiments compared with 9.6 nM in associationiScience 11, 93–113, January 25, 2019 109
experiments). This discrepancy leads us to reject a single-step binding mechanism in favor of the pro-
posed multi-step mechanism.
If relaxin binding is a multi-step mechanism, why was there a linear relationship between kobs versus
the concentration of TamRLX? In the case of a multi-step binding/activation hypothesis, we might expect
an initial diffusion-limited binding interaction between relaxin and RXFP1, followed by one or more confor-
mational rearrangement steps, leading to a final activated relaxin-bound state of RXFP1. Such amechanism
might lead to a hyperbolic relationship between kobs and TamRLX at high-enough ligand concentrations
(Tummino and Copeland, 2008). Or, for example, a two-phase association profile might be encountered
where one phase relates to the initial diffusion-limited ligand binding interaction and the second phase re-
lates to the secondary rate-limited conformational rearrangement step, as has been shown in ligand asso-
ciation experiments with the parathyroid receptor (Castro et al., 2005) and neurokinin A receptor (Palanche
et al., 2001). If a secondary conformational rearrangement step occurs with a very high rate constant (i.e.,
much faster than the off-rate of the initial binding interaction), then it is likely that much higher ligand con-
centrations would be required to observe a two-phase association profile or non-linearity of the kobs versus
TamRLX concentration dependency.
We observed a two-phase dissociation profile of TamRLX from Nanoluc-RXFP1 (Figures 7 and 9), which sug-
gests two relaxin-bound states of RXFP1 and further supports a multi-step binding mechanism. For canonical
GPCRs in which ligand binding is directly coupled to G protein activation, this observation might be explained
as being caused by G protein-coupled and G protein-uncoupled states of the receptor, because G protein
coupling is often associated with an increase in the affinity of bound ligand. However, this explanation is
not sufficient in this case as removal of the LDLa module (which activates the TMD) also showed two-phase
dissociation profiles. In addition, saturation binding experiments in HEK293 cells lacking Gas, the primary G
protein to which RXFP1 is coupled in HEK cells, did not show any significant difference in relaxin binding af-
finity, and previous studies have found no change in relaxin binding affinity in membrane preparations in the
presence of the non-hydrolysable GTP analogs, Gpp(NH)p and GTPgS (Scott et al., 2006). Another alternative
explanation for a two-phase TamRLX dissociation relates to possible homodimerization of RXFP1 (Svendsen
et al., 2008), or differing localization of the receptor within the cell (for example, intracellular pools of receptor,
receptor clustering within different membrane microdomains, or receptor internalization), providing a frame-
work by which two relaxin-binding sites might exist with two slightly different affinities. These explanations also
fall short for three reasons. First, the saturation binding curves for RXFP1 fit very well to a one-site equation.
There is no evidence of a biphasic saturation profile to indicate the presence of two distinct relaxin-binding
sites that may be concomitantly occupied. Second, association experiments clearly showed a monophasic as-
sociation profile at the concentrations tested. The existence and occupancy of two distinct binding sites at the
relaxin concentrations used should in theory produce a more complex association profile. Third, RXFP1 has
been shown to lack arrestin recruitment and does not appear to appreciably internalize upon receptor acti-
vation (Callander et al., 2009; Kern and Bryant-Greenwood, 2008). Thus the evidence suggests relaxin binding
to a single site with a multi-step mechanism rather than simply binding to two distinct sites, which is concor-
dant with the current proposed model for RXFP1 binding/activation (Sethi et al., 2016).
Supporting this idea is our observation that RXFP2, which does not contain a relaxin-linker-binding site,
does not follow a similar two-phase profile of relaxin dissociation, but shows a clear one-phase exponential
decay. Importantly, insertion of RXFP1 linker residues that interact with relaxin clearly increases relaxin af-
finity and activity at the chimeric receptors, whereas TamRLX dissociation assays highlight the reinstate-
ment of a two-phase dissociation profile. These data in conjunction with NMR studies, which show binding
of relaxin to the introduced linker sequence, clearly demonstrate the key role of the linker region in relaxin
affinity and the multi-step binding mechanism. However, it should be emphasized that the relaxin:RXFP1
binding interaction does not appear to be a strictly sequential binding process between the two sites
(i.e., LRR binding followed by linker binding), but rather a concomitant binding interaction over both
LRR/linker domains followed by conformational changes allowing LDLa/linker activation of the TMD.
The linker domain is hence involved in all steps of this process, and this is seen most clearly in our obser-
vation that the RXFP1(F54A/Y58A) mutation in the linker-binding site in RXFP1 also showed a clear two-
phase dissociation of TamRLX (Figure S3) in which both rates were increased compared with wild-type.
Overall, these studies have provided valuable insight into the mechanism by which relaxin binds to RXFP1
and RXFP2, and NanoBRET represents a valuable tool by which these interactions may be investigated in
future. TamRLX association and dissociation experiments provided support for a more complex binding110 iScience 11, 93–113, January 25, 2019
mode than a simple one-step bimolecular interaction, fitting with a hypothesized multi-step model of
relaxin binding/activation. In addition, we found that the LDLa module does subtly influence how relaxin
binds to the receptor, and that it appears to have a role in stabilizing a higher-affinity relaxin-bound state
of the ECD. This may be related to LDLa having interactions with the LRR and/or linker domains, and this
possibility should be investigated in the future.
Limitations of the Study
The requirement of a NanoBRET ligand binding assay is the introduction of tags (Nanoluc on the receptor
and Tamra on relaxin), which may affect how relaxin binds to RXFP1. Indeed, both Nluc-RXFP1 and TamRLX
showed very small perturbations in their respective abilities to be activated by relaxin, and to activate the
untagged receptor (Figures 2A and 2B). The exact rates of relaxin binding presented here will therefore
differ slightly from the ‘‘true’’ rates in an untagged system. Importantly, however, this does not affect inter-
pretations about the relative contributions of each receptor binding domain to the overall relaxin:RXFP1
binding mode (for example, a 50- to 100-fold decrease in relaxin binding affinity when the linker and
LDLa were removed from RXFP1). Furthermore, we are confident that the observed biphasic dissociation
profile of TamRLX from Nluc-RXFP1 truly reflects the interpretation of two relaxin-bound RXFP1 states in
which the linker domain plays an important role, as opposed to simply being an artifact of the NanoBRET
system. This is most clearly demonstrated by the monophasic dissociation profile of TamRLX from Nluc-
RXFP2, which could be converted to a biphasic dissociation profile by introduction of the RXFP1 linker
domain. Hence, although the NanoBRET tags used here may influence the exact rates of binding, we
believe that the interpretations drawn are valid.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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The chemical shift assignments for RXFP2(1-65)- ExLink have been deposited in the BioMagResBank
(http://www.bmrb.wisc.edu) under the accession number 27601.
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Figure S1. Related to Figures 7, 8 and 11. Raw BRET ratios from a single TamRLX 
dissociation experiment at room temperature. (A) HEK293T cells expressing Nanoluc-RXFP1 
were incubated to equilibrium with 1 nM TamRLX before initiation of dissociation by removal of 
unbound TamRLX and addition of 10 µM unlabelled relaxin. (B) Raw BRET ratios were 
normalised such that vehicle only (green) was 0%, no dissociation (black) was 100%, to provide 
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Figure S2. Related to Figure 7: Comparison of different means of initiating TamRLX 
dissociation. HEK293T cells expressing Nanoluc-RXFP1 were incubated to equilibrium with 1 nM 
TamRLX before initiation of dissociation by removal of unbound TamRLX and addition of varying 
concentrations of unlabelled relaxin, or by addition of 10 µM unlabelled relaxin only (without 
removal of unbound TamRLX). Pooled data from 4 to 5 independent experiments performed in 
triplicate and in parallel; error bars represent SEM. Data fit to a biphasic exponential decay 
function in Graphpad prism with no constraints on plateau component, and outputs are presented in 
the accompanying table. Note that there is no significant difference between off-rates (fast or slow), 
nor in the percent of the fast component. Rather, only the plateau component appears to decrease 
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Figure S3. Related to Figure 7: Two-phase dissociation of TamRLX from Nluc-
RXFP1(F54A/Y58A). HEK293T cells expressing Nanoluc-RXFP1(F54A/Y58A) were incubated 
to equilibrium with 10 nM TamRLX before initiation of dissociation by removal of unbound 
TamRLX and addition of varying concentrations of unlabelled relaxin, or by addition of 10 µM 
unlabelled relaxin only (without removal of unbound TamRLX). Pooled data from 4 to 5 
independent experiments performed in triplicate and in parallel; error bars represent SEM. Data fit 
to a biphasic exponential decay function in Graphpad prism with no constraints on plateau 
component, and outputs are presented in the accompanying table.  
  
 
Figure S4. Related to Figure 12. Saturation curves from titration of relaxin into RXFP2(1-65)-
ExLink. Kd values were extracted from curves of chemical shift movement of residues Ile50 





Figure S5. Related to Figure 12. (A) Full 1H, 15N HSQC spectrum of RXFP2(1-65)ExLink with 
residue assignments. Unassigned resonances in the upper right corner belong to Asn and Gln 
sidechains. Residues I2 to E73 correspond to the LDLa-linker while residues Q74 to E128 belong 
to the GB1 tag. (B) and (C): Representative regions of the 1H, 15N HSQC spectrum showing 




Supplemental information – ORF amino acid sequences for Nanoluc-RXFP1 and Nanoluc-
RXFP2 constructs used in this study, inserted in pcDNA3.1/Zeo plasmid, as well as His6-GB1-
RXFP2(1-65)-ExLink protein construct, inserted in pET15 plasmid. 
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Cell culture and transfection 
HEK293T cells (ATCC #CRL-1573; American Type Tissue Culture Collection) and a HEK293A 
cell line with CRISPR deletion of GNAS (HEK293A Gαs; (Stallaert et al., 2017)) were grown in 
complete medium (Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich) supplemented 
with 10% FBS, 1% L-glutamine, and 1%  penicillin/streptomycin) and maintained 37 °C incubators 
with 5% CO2. For receptor expression, cells were first seeded into 6-well plates at a density of 6 X 
105 cells/well. The following day, cells were transfected with receptor DNA using LipofectAMINE 
2000 (Invitrogen, Carlsbad, CA), usually with 10-30 ng DNA per well unless otherwise stated. 
Nanoluc RXFP2 and variants were transfected using polyethylenimine (PEI; Sigma-Aldrich) with 
500 ng DNA per well and a ratio of 4.5 µl PEI per µg of DNA. 24-hours post-transfection, cells 
were resuspended and seeded into 96-well optiplates for assay the following day.   
TamRLX synthesis 
Individual A- and B-chains of H2 relaxin with appropriate regioselective S-protection were 
synthesized using a CEM Liberty peptide synthesizer (Akhter Hossain et al., 2008). Upon complete 
coupling and Fmoc deprotection of the final amino acid, glutamine (Q), at the N-terminus of the A-
chain sequence, the amine-reactive fluorophore 5(6)-TAMRA succinimidyl ester (Anaspec) was 
attached using manual coupling procedure. Following final TFA cleavage and purification of the 
crude peptides (TAMRA A-chain and B-chain), stepwise formation of the three disulfide bonds 
was conducted via oxidation, thiolysis and iodolysis consecutively (Akhter Hossain et al., 2008). 
The final TAMRA-labelled relaxin, TamRLX, was subjected to comprehensive characterization by 
RP-HPLC and MALDI-TOF mass spectrometry to confirm its high purity and correct molecular 
mass (m/z calculated for TamRLX [M+Na]+, 6415.456, found 6419.70). 
Receptor construct cloning 
All receptor constructs were cloned in pcDNA3.1/Zeo (Invitrogen) plasmids and contained an N-
terminal FLAG tag as well as the non-native bovine prolactin signal peptide to aid receptor 
expression as previously described for both RXFP1 and ECD-only (previously termed 7BP) (Hsu et 
al., 2002). The gene for Nanoluc was synthesised (GenScript Corp., Nanjing, China) and inserted 
between the FLAG tag and LDLa module via the insertion of an EcoRI restriction site using 
standard restriction enzyme based cloning methods. For RXFP2 and constructs in which the LDLa 
and/or the linker domain had been removed, PCR products encoding the relevant receptor and stop 
codon were inserted C-terminally to the Nanoluc in a pcDNA3.1/Zeo vector containing signal 
peptide, FLAG tag and Nanoluc. Receptor mutations (F54A/58A and E277Q/D279N) were 
achieved by QuikChange mutagenesis with PrimeStar polymerase (Takara Clontech, Mountain 
View, CA) according to manufacturer’s instructions and similarly to previously described (Sethi et 
al., 2016). RXFP2 extended linker (ExLink) chimeras were made according to the method 
described in (Liu and Naismith, 2008) whereby primers were designed with short overlapping 
sections with Tm 5-10 ° C lower than that of non-overlapping sections in either direction. PCR 
reaction mixes of 50 µl were subjected to the following protocol: 5 min at 95 °C; 12 cycles of 95 
°C (1 min), 53 °C (1 min), 68 °C (12 min); 1 min at 43 °C followed by a further extension step at 
68 °C for 30 min, and 4 °C hold.  All receptor constructs were verified by sequencing across the 
entirety of the ORF, and full amino acid sequences of receptor constructs are provided in 
supplemental information.  
 
cAMP reporter gene assay 
cAMP activity in HEK293T cells expressing receptors in response to ligand stimulation was 
measured using a pCRE β-gal reporter gene assay (Chen et al., 1995). For RXFP1 and mutants 
HEK293T cells were prepared for assay according to transfection methods described above, but 
were transfected with 50 ng / well of receptor DNA and 2 µg/well of pCRE β-gal DNA. RXFP2 
and ExLink chimeras were tested using conditions described in (Bruell et al., 2017). Briefly, cells 
were seeded at 25,000 cells per well in 96-well Cellbind plates (Corning) and the following day 
transfected with LipofectAMINE 2000 at 0.5 µl per well and 0.25 µg DNA per well, divided in 
proportions of 1:2:5 of receptor, β-gal and pcDNA3.1 (empty) vector. For experiments in which 
relaxin was compared to TamRLX, a HEK293T cell line stably expressing RXFP1 and pCRE β-gal 
was instead used. On the day following seeding into 96-well plates, cells were treated with 5 µM 
forskolin (as a receptor independent control for response normalisation) or increasing 
concentrations of relaxin in complete medium. For assays of ML290-induced cAMP activity, 
dilutions were prepared in dimethyl sulphoxide (DMSO) and added to minimal media (DMEM 
containing 0.5% foetal bovine serum, 1% L-glutamine, 1% penicillin/streptomycin) such that wells 
contained 1% final DMSO concentration. Cells were incubated with ligands at 37 °C for 6 h, after 
which media was aspirated and the cells frozen at -80 °C overnight. The amount of cAMP-driven 
β-gal expression was determined by lysing cells in 25 µL/well of assay buffer 1 (10 mM Na2PO4, 
pH 8.0, 0.2 mM MgSO4, 0.01 mM MnCl2) for 10 min, followed by 100 µL/well of assay buffer 2 
(100 mM Na2PO4, pH 8.0, 2 mM MgSO4, 0.1 mM MnCl2, 0.5 % Triton X-100, 40 mM β-
mercaptoethanol) for a further 10 min before the addition of 25 µL/well of enzyme substrate 
solution (1 mg / ml chlorophenol red β-D-galactopyranoside in assay buffer 2). The absorbance of 
each well was monitored using a Benchmark Plus Microplate Reader (Bio-Rad, Hercules, CA) at 
570 nm. Experiments were performed in triplicate at least 3 times, and data were pooled and 
presented as percentages of the response induced by 5 µM forskolin. Data was fit to a three-
parameter sigmoidal dose-response curve using GraphPad Prism to yield pEC50 and Emax values. 
Statistical significance was assessed by ordinary one-way analysis of variance (ANOVA) and 
uncorrected Fisher’s least squares difference (LSD) multiple comparison test. 
 
 BRET measurements 
 
All BRET measurements were performed in POLARstar Omega plate reader (BMG Labtech) 
equipped with emission filters for the ‘donor’ (410-490 nm) and ‘acceptor’ (>610 nm long-pass) 
luminescence emission. BRET ratio was defined as the ratio of the acceptor emission over the 
donor emission.   
NanoBRET saturation binding assays 
Transfected cells in 96-well plates (prepared according to transfection methods described above) 
were first washed with 100 µL/well of PBS (pH 7.4) and incubated with 90 µL /well of assay buffer 
(Phenol-red free DMEM containing 10% FBS, 1% L-glutamine, 1%  penicillin/streptomycin, 25 
mM HEPES, pH 7.4 for RXFP1 and variants; or 20mM HEPES, pH 7.5, 1.5 mM CaCl2, 50 mM 
NaCl containing 1% BSA for RXFP2 and variants) containing varying concentrations of TamRLX 
(with or without an excess of unlabelled relaxin to determine non-specific binding signal) for 90 
minutes, either at room temperature or 37 °C. Following incubation, 10 µL/well of assay buffer 
containing a 1:50 dilution Nano-Glo luciferase substrate (Promega Corporation, Fitchburg, WI) 
was added, followed by BRET measurement. BRET ratios were fit using a “One-site – Total and 
nonspecific binding” saturation binding equation in GraphPad Prism (La Jolla, CA) to yield 
dissociation constants (Kd). Statistical significance was assessed by ordinary one-way ANOVA and 
uncorrected Fisher’s LSD multiple comparison test of pooled pKd values.  
 
NanoBRET association assays 
Transfected cells in 96-well plates (prepared according to transfection methods described above) 
were first washed with 100 µL/well of PBS (pH 7.4) and then 100 µL/well of assay buffer 
containing a 1:500 dilution of Nano-Glo luciferase substrate was added. BRET measurements were 
performed in a POLARStar Omega plate reader every minute for 15 minutes, before manual 
addition of 50 µL of assay buffer containing varying concentrations of TamRLX (or vehicle only) 
and a 1:500 dilution of Nano-Glo luciferase substrate, with further BRET measurements every 
minute for 60 more minutes.  
NanoBRET dissociation assays 
Transfected cells in 96-well plates (prepared according to transfection methods described above) 
were first washed with 100 µL / well of PBS (pH 7.4), then 100 µL of assay buffer containing a 
1:500 dilution of Nano-Glo luciferase substrate (plus or minus TamRLX) was added, with BRET 
measurement every minute. For RXFP1 experiments at room temperature, 1 nM TamRLX was 
used and dissociation was initiated after 60 minutes of incubation with BRET measurements by 
removal of buffer in all wells and replacement with assay buffer containing a 1:500 dilution of 
Nano-Glo luciferase substrate and 10 µM unlabelled relaxin (to normalise data, “non-dissociation” 
wells were included in which the same concentration of TamRLX was added back, without the 
unlabelled relaxin). For RXFP2 experiments 13 nM TamRLX was used and due to the faster speed 
of dissociation, 2 µM unlabelled INSL3 was added directly into wells after 15 minutes of 
incubation with BRET measurements. For experiments at 37 °C, 5 nM of TamRLX was used and 
dissociation was instead initiated by automated injection of 3 µL/well of 1 mg/mL unlabelled 
relaxin (to a final concentration of roughly 5 µM) after 30 minutes of BRET measurements. Data 
was pooled and presented as mean ± SEM of at least three independent experiments each 
performed in triplicate. Dissociation was normalized to wells containing TamRLX with no 
dissociation (100%) and buffer containing vehicle only (0%), all in the presence of substrate. 
Curves were fit using GraphPad Prism with a one-site and then a two-site exponential decay 
function, with goodness of fit being assessed by observation of associated mean residual plots. Off-
rates were extracted as koff for one-site curves, and koff FAST, and koff SLOW along with % Fast for 
two-site curves. Where applicable, statistical significance was calculated using ordinary one-way 
ANOVA and uncorrected Fisher’s LSD multiple comparison test. 
Protein expression and purification 
Our NMR analysis made use of the same construct described and characterized by us in (Bruell et 
al., 2017), which consists of the first 65 residues of human RXFP2, constituting the LDLa module 
and linker, with residue Pro4 mutated to Phe to give a homogeneous spectrum without interfering 
with activity, and a C-terminal GB1 solubility and stabilization tag. We refer to this construct as 
RXFP2(1-65) and append the name ExLink to denote the insertion of seven RXFP1 linker residues 
(see supporting information). We inserted linker residues into RXFP2(1-65)-ExLink in two rounds of 
site-directed mutagenesis, as described above for the whole receptor. Once the sequence had been 
confirmed the construct was expressed in BL21(DE3)-trxB cells as described in (Bruell et al., 
2017). Protein purification proceeded as previously described, making use of the N-terminal HIS 
tag which was bound to Talon Superflow resin (Takara Clontech), then washed and eluted in 400 
mM imidazole in 20 mM Tris-HCl (pH7.4), 150 mM NaCl. The eluted protein was then re-folded 
overnight in a mixed redox reaction, and the following night the HIS tag and N-terminal GB1 tag 
were removed with 5 units of thrombin per mg of protein. A run through an Agilent Zorbax 300SB-
C18 column on reverse phase high performance liquid chromatography (RP-HPLC) further purified 
the final product which was verified by mass spectrometry for correct molecular weight and purity 
before being lyophilized and stored at -20 °C. 
NMR Spectroscopy 
NMR experiments were all performed at 25 °C on a 700 MHz Bruker Avance HDIII or Bruker 
Avance II HD 800 MHz spectrometer each equipped with a triple resonance cryoprobe. Proteins 
were dissolved in 50 mM imidazole, 10 mM CaCl2 at pH 6.8. Backbone resonances (13Cα, 13Cβ, 
13C', 15N and NH) of the residues of RXFP2(1-65)-ExLink were assigned from 3D HNCACB, 
HN(CO)CACB, HNCO and HN(CA)CO experiments using non-uniform sampling (NUS) at 800 
MHz. For NUS, sampling schedules were generated using poisson gap sampler with 10% of the 
total number of points collected for all the 3D NMR experiments (Hyberts et al., 2010). Spectra 
were reconstructed with compressed sensing algorithm using qMDD (Kazimierczuk and Orekhov, 
2011) and processed using NMRPipe (Delaglio et al., 1995) as described in (Sethi et al., 2016) and 
data analyzed in SPARKY (Lee et al., 2015). The chemical shift assignments for RXFP2(1-65)-
ExLink have been deposited in the BioMagResBank (http://www.bmrb.wisc.edu) under the 
accession number 27601. Samples for titrations were dialyzed in the same buffer. Chemical shift 
and intensity changes were monitored via the acquisition of 2D 1H-15N Heteronuclear Single 
Quantum Coherence (HSQC) as described for RXFP1(1–72) in (Kay et al., 1989), using increasing 
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